RxDoctor Payments Data

Matthew Klinge, MD

Gastroenterology · Erie, PANPI 1457693533

Payments from drug & device makers

$2,434in general payments, 2019–2025

Across 118 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$303
  • Boston Scientific$189
  • Capsovision, Inc.$111
  • Takeda Pharmaceuticals U.S.A., Inc.$107
  • Ironwood Pharmaceuticals, Inc$94
  • plus $291 from 6 others

What the payments were for

  • Food & beverage$2,31395%
  • Education$1225%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,434 in reported general payments places this provider in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$192,481
Medicare patients
465
Services billed
4,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$333,429
XifaxanRifaximin64$195,869
XeljanzTofacitinib Citrate11$73,866
CreonLipase/Protease/Amylase21$56,494
Ursodiol119$18,757
LinzessLinaclotide20$15,130
Mesalamine16$7,503
Tacrolimus75$6,031
Entecavir17$5,237
Pantoprazole Sodium522$4,382
Balsalazide Disodium16$2,939
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates44$2,912
Sucralfate26$2,884
Dexlansoprazole DrDexlansoprazole16$2,723
Colestipol Hcl14$1,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,339$333,42913 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$41$195,86964 claims
PfizerXeljanz$66$73,86611 claims
AbbVieCreon, Linzess$303$71,62441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →